A phase I, sequential cohort, dose escalation trial to determine the safety, tolerability, and maximum tolerated dose of daily oral administration of AV-412 in patients with refractory or relapsed solid tumor malignancies
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2011
At a glance
- Drugs AV 412 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Jan 2009 Planned end date changed from Mar 2009 to Mar 2010 as reported by ClinicalTrials.gov.
- 10 Oct 2006 New trial record.